Page 168 - Drug Class Review
P. 168
Page 114 of 205
Drug Effectiveness Review Project
Authors and Year: Rockwood et al., 2001; 51 Markowitz et al., 2003 63
placebo N/A 3 months 125 History of cognitive decline over the last 6 months; diagnosis of probable AD according to NINCDS/ADRDA; presence of mild to moderate dementia; MMSE of 11- 24; > 2 on ADAS-Cog; Concomitant medical disease; other neurodegenerative disorder; previously treated with cholinomimetic All drugs except anticholinergic or cholinomimetic drugs were permitted; psychotropic drugs had to be
Drugs Country: Multinational Janssen Research Foundation To assess the efficacy and safety of GAL in AD Setting: Multi-center (43 centers in 6 countries) galantamine 24 – 32 mg/d 3 months 261 contact with a responsible caregiver agents except muscarinic agonists discontinued 48 hours before cognitive evaluation
Alzheimer Study design: RCT Sample size: 386
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
